CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 477 enrolled
Drug / intervention
Pembrolizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02054806
NCT02054806Phase 1Completed
CompareCT.gov

Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors

Merck Sharp & Dohme LLC·interventional·Posted Feb 4, 2014·Updated Oct 30, 2023

In Brief

A Phase 1 clinical trial evaluating Pembrolizumab for Solid Tumor. Completed, enrolled 477 participants.

Detailed Summary

This study will assess the efficacy and safety of pembrolizumab (MK-3475) administered to participants with incurable advanced biomarker-positive solid tumors that have not responded to current therapy or for which current therapy is not appropriate. The study hypothesis is that administration of pembrolizumab to participants with some types of solid tumors will result in a clinically meaningful response rate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 4, 2014
Enrollment StartFeb 17, 2014
Primary CompletionApr 30, 2021
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 12.4 years ago

Interventions

Pembrolizumabbiological

IV infusion